# kidney disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/kidney-disease

> 2 upcoming FDA catalysts in kidney disease: mezagitamab (TAK) on Sep to Dec 2028 (topline data readout); mezagitamab (TAK) on September 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 28, 2025 | [Oxylanthanum complete response letter (CRL)](https://sec-api.dev/pdufa/oxylanthanum) | UNCY | kidney disease | completed, complete response letter | "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm)) |
| Sep to Dec 2028 | [Mezagitamab topline data readout](https://sec-api.dev/pdufa/mezagitamab) | TAK | Kidney Disease | scheduled | "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963827)) |
| September 2028 | [Mezagitamab primary completion](https://sec-api.dev/pdufa/mezagitamab) | TAK | Kidney Disease | scheduled | "NCT06963827 (A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-07 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963827)) |

## Drugs

- [Oxylanthanum](https://sec-api.dev/pdufa/oxylanthanum) (UNCY)
- [Mezagitamab](https://sec-api.dev/pdufa/mezagitamab) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/kidney-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "kidney disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/kidney-disease

```bibtex
@misc{secapidev_indications_kidney_disease_20261116,
  title        = {kidney disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/kidney-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_kidney_disease_20261116","title":"kidney disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/kidney-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
